arrow
S

Simon Call

university of munster
H指数:6
被引数:149

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland – part II – expert based recommendations for surveillance and management of side-effects

德国、奥地利和瑞士关于使用onasemnogene abeparvovec进行脊髓性肌萎缩基因治疗的德尔菲共识——第二部分——基于专家的建议:副作用监测和管理

2026-08-270
PRE
Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemia

异基因造血干细胞移植后活动性急性髓系白血病患者的复发

2025-12-010
OAAI
Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning

接受曲奥舒凡或TBI为基础预处理方案的异基因造血细胞移植(allo-HCT)的AML和MDS患者的免疫重建

2025-08-220
OAAI
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis

伊decabtagene vicleucel在复发/难治性多发性骨髓瘤伴先前中枢神经系统表现患者中的疗效:一项多中心真实世界分析

2025-08-180
OA
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

缓解转换驱动多发性骨髓瘤CAR T细胞疗法的结局:来自DRST登记研究的分析

Blood
IF23.1
2025-06-140
OA
High-dose melphalan followed by busulfan and fludarabine conditioning prior to allogeneic stem cell transplantation in elderly patients with active AML – a retrospective single center study

大剂量美法仑后接白消安和氟达拉滨预处理,用于老年活动性急性髓系白血病患者异基因干细胞移植——一项回顾性单中心研究

2025-06-010
OAAI
Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

伊decabtagene vicleucel(ide-cel)在复发/难治性多发性骨髓瘤且伴有先前中枢神经系统表现患者中的疗效:一项回顾性真实世界分析

BLOOD
IF23.1
2024-11-050
PRE
Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study
2024-03-207
OAAI